Optimized lipid nanoparticles for CRISPR/Cas9 delivery: advancing gene editing in lung tumor cells

Lung cancer remains a leading cause of cancer-related deaths worldwide, with KRAS mutations present in 15-30% of cases. These mutations often exhibit resistance to standard therapies, leading to poor prognosis and reduced survival [1,2]. The advent of CRISPR/Cas9 technology offers a promising approach for precise gene editing, particularly for undruggable targets such as KRAS mutations [3]. This study focuses on optimizing lipid nanoparticles (LNPs) to enhance the delivery and efficacy of CRISPR/Cas9 systems for gene editing in lung tumor cells.